Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous revision label. This reflects a minor update to the document without altering its content.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check68 days agoChange DetectedSite revision updated from version v3.4.3 to v3.5.0. No visible changes to the study details or page content.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.1%

- Check104 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no core content or functionality changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.